Genomics of high-risk myeloma

Multiple Myeloma Hub
23/06/2020 15 min
Genomics of high-risk myeloma

Listen "Genomics of high-risk myeloma"

Descargar episodio Ver en sitio original

Episode Synopsis

During COMy 2020, Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about genomics of high-risk MM.Here, Nikhil Munshi highlights the positive shift in survival outcomes of patients with high-risk MM in recent years, owing to emerging treatments and diagnostic techniques. Three major points are discussed:1. Who is high risk?2. What are the characteristics of high-risk MM?3. How do we treat patients with high-risk disease? Hosted on Acast. See acast.com/privacy for more information.

More episodes of the podcast Multiple Myeloma Hub

Clinical experience with belantamab mafodotin: Management strategies for ocular toxicity 23/10/2025
MIDAS: MRD-driven strategy after Isa-KRd induction in ND ASCT-eligible MM 22/10/2025
How might the clinical development of CELMoDs impact the treatment paradigm for MM? 20/10/2025
CARTITUDE-2: Cilta-cel ± Len maintenance for MM with suboptimal response to ASCT 03/10/2025
Evolving diagnostic criteria for high-risk smoldering MM 30/09/2025
What combination regimens including BiTEs are being evaluated for the treatment of RRMM? 17/09/2025
Risk stratification and prognosis in smoldering MM 10/09/2025
What combination regimens containing BCMA-directed bispecific antibodies are being evaluated for MM? 09/09/2025
How can neurotoxicity associated with CAR T-cell therapy in MM be managed? 26/08/2025
What might be the future applications for BCMA-directed bispecific antibodies in MM and other PCD? 18/08/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA